a partial agonist, unlike many current agonists that focus more on D2 and D3 receptors. This difference in mechanism is being studied for its potential impact on symptom control and side effect profiles.
Is tavapadon available now? No, it remains investigational. The FDA is reviewing the New Drug Application submitted in 2025. Approval decisions and availability timelines will be announced officially.What should I discuss with my doctor about new Parkinson’s options? Bring up your current symptom patterns, any side effects you experience, and your interest in once-daily therapies. Your